189 related articles for article (PubMed ID: 17638920)
1. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
2. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Cao YY; Ge H; Chen LQ; Chen ZF; Wen DG; Li Y; Zhang JH
Ai Zheng; 2007 Oct; 26(10):1052-7. PubMed ID: 17927872
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
5. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
6. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
7. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
8. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
9. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
10. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
[TBL] [Abstract][Full Text] [Related]
11. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
[TBL] [Abstract][Full Text] [Related]
13. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
[TBL] [Abstract][Full Text] [Related]
14. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.
Cai X; Yang M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):555-61. PubMed ID: 22205265
[TBL] [Abstract][Full Text] [Related]
15. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
16. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
[TBL] [Abstract][Full Text] [Related]
17. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women.
Singh V; Rastogi N; Mathur N; Singh K; Singh MP
Ann Epidemiol; 2008 Jan; 18(1):48-57. PubMed ID: 17719241
[TBL] [Abstract][Full Text] [Related]
18. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
